請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45456
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 何?芳 | |
dc.contributor.author | Wen-Chun Lin | en |
dc.contributor.author | 林玟君 | zh_TW |
dc.date.accessioned | 2021-06-15T04:21:09Z | - |
dc.date.available | 2010-03-12 | |
dc.date.copyright | 2010-03-12 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-10-21 | |
dc.identifier.citation | 1. 行政院衛生署:衛生統計資訊網-醫療品質(2009/4/30)。臺北:衛生署,2009。Available at: http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=9775&class_no=440&level_no=1. (accessed 2009 May 22)
2. American Pharmacists Association, National Association of Chain Drug Stores Foundation: Medication therapy management in pharmacy practice: core elements of an MTM service model. Version 2.0; 2008. 3. Noyce PR: Providing patient care through community pharmacies in the UK: policy, practice, and research. Annals of Pharmacotherpy. 2007;41:861-8. 4. Benrimoj SI, Roberts AS: Providing patient care in community pharmacies in Australia. Annals of Pharmacotherpy 2005;39:1911-1917. 5. 陳鈴潔:臺北縣基層藥事執業調劑品質調查研究 [碩士論文];指導教授:何藴芳助理教授(國立臺灣大學),2008。 6. 行政院衛生署:藥品優良調劑作業準則,衛署藥字第0930332950號。臺北:衛生署。93年11月25日發布。Available at: http://dohlaw.doh.gov.tw/Chi/FLAW/FLAWDAT01.asp?lsid=FL033109 (accessed 2009 May 22). 7. International Pharmaceutical Federation: Standards for Quality of Pharmacy: Good Pharmacy Practice; 1997. 8. 行政院衛生署:優良藥品調劑作業規範,衛署藥字第0900071491號,90年11月2日發布。臺北:衛生署。Available at: http://db.lawbank.com.tw/FLAW/FLAWDAT01.asp?lsid=FL013866 (accessed 2009 May 22). 9. Carmichael J, Jones W: Medication therapy and patient care. In: Brown T, ed. Handbook of institutional pharmacy practices. 4th ed. Bethesda: American Society of Health-System Pharmacists; 2006:143-54. 10. Stewart RB: Polypharmacy in the elderly: a fait accompli? Drug Intelligence and Clinical Pharmacy 1990;24:321-23. 11. 董千儀、林慧玲、林昌誠、林素真、何藴芳:民眾對醫院與社區藥局慢性病連續處方調劑服務的觀感。臺灣醫學 2008;12:635-43。 12. Hammerlein A, Griese N, Schulz M: Survey of drug-related problems identified by community pharmacies. Annals of Pharmacotherpy 2007;41:1825-32. 13. Doucette WR, McDonough RP, Klepser D, McCarthy R: Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy. Clinical Therapeutics 2005:27:1104-11. 14. Zarowitz BJ, Stebelsky LA, Muma BK, et al: Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting.. Pharmacotherapy 2005;25:1636-45. 15. Paulino EI, Bouvy ML, Gastelurrutia MA, et al: Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharmacy World & Science 2004;26:353-60. 16. Lin HY, Lao CC, Cheng SH, Wang PC, Hsueh YS: Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a Taiwanese medical setting. Drugs Aging 2008;25:49-59. 17. Hawksworth GM, Corlett AJ, Wright DJ, Chrystyn H: Clinical pharmacy interventions by community pharmacists during the dispensing process. British Journal of Clinical Pharmacology 1999;47:695-700. 18. 林慧玲、高雅慧、吳如琇、游文瑛、陳文慧、陳瓊雪:在台灣建立一個較安全的用藥制度。台灣醫學 2002;6:924-37。 19. Department of Health NYS: Annual Report of the New York State Durg Utilization Review Board 2007. 20. Long AJ, Chang P, Li YC, Chiu WT: The use of a CPOE log for the analysis of physicians' behavior when responding to drug-duplication reminders. International Journal of Medical Informatics 2008;77:499-506. 21. Alkema GE, Wilber KH, Simmons WJ, Enguidanos SM, Frey D: Prevalence of potential medication problems among dually eligible older adults in Medicaid Waiver services. Annals of Pharmacotherpy 2007;41:1971-8. 22. 林慧玲、朱蓁蓁、高純琇、何藴芳、游文瑛、黃甄彥、蘇錦玲、陳春雄:用藥風險的避免。台灣醫學 2002;6:228-42。 23. Buurma H, Smet PAGMD, Leufkens HGM, Egberts ACG: Evaluation of the clinical value of pharmacists' modifications of prescription errors. British Journal of Clinical Pharmacology 2004;58:503-11. 24. Buurma H, Smet PAGMD, Hoff OPVD, Egberts ACG: Nature, frequency and determinants of prescription modifications in Dutch community pharmacies. British Journal of Clinical Pharmacology 2001;52:85-91. 25. 全民健康保險爭議審議委員會:不同科別重複用藥所涉及之爭議問題。醫療品質雜誌 2007;1:74-81。 26. 中央健康保險局:最新健保數據-醫療服務品質。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=1&menu_id=4&webdata_id=805&WD_ID=4. (accessed 2009 July 15). 27. International Diabetes Federation: Prevalence DM and IGT. Brussels: International Diabetes Federation. Available at: http://www.eatlas.idf.org/index.html. (accessed 2009 June 12). 28. 行政院衛生署新聞:65歲以上男性糖尿病盛行率達28.5% 衛生署呼籲控制體重 多運動多蔬果。Available at: http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=25&now_fod_list_no=10404&level_no=2&doc_no=71692. (accessed 2009 June 6). 29. Nathan DM, Buse JB, Davidson MB, et al: Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193-203. 30. Pharmacy Quality Alliances: Endorsed measures, survey instruments and reports. Available at: http://www.pqaalliance.org/nov20meeting.htm. (accessed 2009 May 20). 31. 中央健康保險局:94年全民健康保險糖尿病專業醫療服務品質報告。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=5&menu_id=396&webdata_id=848&WD_ID=. (accessed 2009 June 8). 32. 中央健康保險局:藥品代碼與ATC碼對照。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=3&menu_id=56&webdata_id=1139&WD_ID=. (accessed 2009 June 10). 33. 國民健康局:糖尿病共同照護工作指引手冊。臺北:衛生署。Available at: http://www.bhp.doh.gov.tw/BHPnet/Portal/Them.aspx?No=200712250011. (accessed 2009 June 12). 34. American Diabetes Association: Standards of medical care in diabetes - 2009. Diabetes Care 2009;32:S13-S61. 35. Mehuys E, De Bolle L, Van Bortel L, et al: Medication use and disease management of type 2 diabetes in Belgium. Pharmacy World & Science 2008;30:51-6. 36. Krass I, Armour CL, Mitchell B, et al: The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabetic Medicine 2007;24:677-83. 37. Fornos JA, Andres NF, Andres JC, et al: A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharmacy World & Science 2006;28:65-72. 38. Mehta BH, Rodis JL, Nahata MC, et al: Advancing patient care through innovative practice: the Clinical Partners Program. American Journal of Health-System Pharmacy. 2005;62:2501-7. 39. Saseen JJ, Maclaughlin EJ: Hypertension. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach; 7th ed. New York: McGraw Hill, 2008:139-71. 40. 國民健康局:高血壓防治手冊-高血壓偵測、控制與治療流程指引。臺北:衛生署。Available at: http://www.bhp.doh.gov.tw/bhpnet/portal/Them_Show.aspx?Subject=200712250015&Class=2&No=200712250090. (accessed 2009 June 17). 41. 行政院衛生署新聞:97年國人主要死因統計-依國際疾病傷害及死因分類標準第10版編碼。臺北:衛生署。Available at: http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=25&level_no=1&doc_no=71722. (accessed 2009 June 17). 42. 行政院衛生署:衛生統計資訊網-94年全民健康保險醫療統計年報。臺北:衛生署。Available at: http://www.doh.gov.tw/CHT2006/DM/SEARCH_RESULT.aspx. (accessed 2009 June 17). 43. Rosendorff C, Black HR, Cannon CP, et al: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007;115:2761-88. 44. Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52. 45. 中央健康保險局:94年門診高血壓用藥品質報告。臺北:中央健康保險局。Available at: http://www.google.com/search?q=wow+usb+protector&ie=utf-8&oe=utf-8. (accessed 2009 July 15). 46. World Health Organization: Pharmacy-based hypertension management model: Protocol and guidelines. Geneva: WHO. Available at: http://www.euro.who.int/document/e85730.pdf. (accessed 2009 June 15). 47. Lam AY: Assessing medication consultations, hypertension control, awareness, and treatment among elderly Asian community dwellers. Consultant Pharmacist 2008;23:795-803. 48. Bunting BA, Smith BH, Sutherland SE, Bunting BA, Smith BH, Sutherland SE: The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. Journal of the American Pharmacists Association 2008;48:23-31. 49. Planas LG, Crosby KM, Mitchell KD, Farmer KC: Evaluation of a hypertension medication therapy management program in patients with diabetes. Journal of the American Pharmacists Association 2009;49:164-70. 50. Talbert RL: Hyperlipidemia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach; 7th ed. New York: McGraw Hill, 2008:385-408. 51. 國民健康局:高血脂防治手冊國人血脂異常診療及預防指引。臺北:衛生署。Available at: http://www.bhp.doh.gov.tw/BHPnet/Portal/Them_Show.aspx?Subject=200712250016&Class=2&No=200712250093. (accessed 2009 June 21). 52. Expert panel on detection evaluation, treatment of high blood cholesterol in adults: executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). The Journal of American Medical Association 2001;285:2486-97. 53. Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Canadian Medical Association Journal 2003;169:921-4. 54. Bottorff M: ‘Fire and forget?’ - pharmacological considerations in coronary care. Atherosclerosis 1999;147:S23-S30. 55. Muscari A, Puddu GM, Puddu P: Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002;97:115-21. 56. Tatro DS. Drug Interaction Facts. St. Louis: Facts and Comparisons; 2005. 57. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. The Journal of American Medical Association 2002;288:455-61. 58. Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F: Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. Clinical Therapeutics 2008;30:761-74. 59. 中央健康保險局:醫療品質資訊停看聽。臺北:中央健康保險局。Available at: http://www.nhitb.gov.tw/mquality/index_main.asp. (accessed 2009 June 24). 60. Tsuyuki RT, Olson KL, Dubyk AM, Schindel TJ, Johnson JA: Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). The American Journal of Medicine 2004;116:130-3. 61. Charrois TL, Johnson JA, Blitz S, Tsuyuki RT: Relationship between number, timing, and type of pharmacist interventions and patient outcomes. American Journal of Health-System Pharmacy 2005;62:1798. 62. 行政院衛生署:藥師法,總統華總一義第09600035241號令;96年3月21日修正(三十二年九月三十日國民政府制定公布)。臺北:衛生署。Available at: http://dohlaw.doh.gov.tw/Chi/FLAW/FLAWDAT01.asp?lsid=FL013519. (accessed 2009 May 20). 63. 法務部全球資訊網:法務部積極清查「門前藥局」弊端。Available at: http://www.moj.gov.tw/ct.asp?xItem=56143&ctNode=79&mp=203. (accessed 2009 May 24). 64. 中央健保局:健保審字第0940034614號。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/PDA/bbs_detail.asp?Bulletin_ID=538&menu=1&menu_id=&PageC=86. (accessed 2009 July 14). 65 行政院衛生署新聞:推動處方交付就醫者,提升藥事服務品質。Available at: http://www.doh.gov.tw/CHT2006/DM/SEARCH_RESULT.aspx. (accessed 2009 May 30). 66. 黃雋恩:北縣諮詢站,迎接居家照護新挑戰。藥師週刊97年6月9日;1575期。 67. Flower:嘉義市長照獲民視異言堂青睞。藥師週刊97年5月5日;1570期。 68. 陳映伶:高縣家庭藥師的秘密武器 -- 社區醫療巡迴車。藥師週刊98年4月13日;1617期。 69. 陳逸芬:社區藥局藥師介入民眾藥事服務之成果評估-以醫藥合作試辦群為例 [碩士論文];指導教授:林妍如(中國醫藥大學)2008. 70. Christensen DB, Farris KB. Pharmaceutical Care in Community Pharmacies: Practice and Research in the US. Annals of Pharmacotherpy. 2006;40:1400-6. 71. Yamamura S, Yamamoto N, Oide S, Kitazawa S. Current State of Community Pharmacy in Japan: Practice, Research, and Future Opportunities or Challenges. Annals of Pharmacotherpy 2006;40(11):2008-14. 72. Japan Pharmaceutical Association: Annual Report of Japan Pharmaceutical Association. Tokyo: Japan Pharmaceutical Association. 2006. 73. Pharmaceutical Society of Australia: Professional Practice Standard. Version 3. 3rd ed. 2006. Deakin: Pharmaceutical Society of Australia. Available at: http://www.psa.org.au/site.php?id=38 (accessed: 2008/11/26). 74. Pharmaceutical Society of Australia: Competency Standards for Pharmacists in Australia. 2003. Deakin: Pharmaceutical Society of Australia. Available at: http://www.pharmacyboard.qld.gov.au/publications.htm (accessed: 2008/11/26). 75. Pharmaceutical Society of Australia: Pharmacy Training Manual: Pharmacy Medicines, Pharmacist Only Medicines. Deakin: Pharmaceutical Society of Australia. 76. Pharmaceutical Society of Australia: Guidelines and Standards for Pharmacists: Medication Profilling Services. 2007. Deakin: Pharmaceutical Society of Australia. 77. 藥師週刊:全聯會藥事照護應納入長期照護保險體系說帖。藥師週刊98年4月20日;1618期。 78. 國家衛生研究院:全民健康保險研究資料庫 - 承保抽樣歸人檔。Available at: http://w3.nhri.org.tw/nhird/date_cohort.htm. (accessed 2009 May 30). 79. McEvoy GK, Snow EK: American Hospital Formulary Service Drug Information. Bethesda: Authority of the Board of the American Society of Health-System Pharmacists; 2009. Available at: http://online.statref.com/TOC/TOC.aspx?FxId=1&SessionId=FA8551AGAKHSGSHQ. (accessed 2009 March 31). 80. Sweetman SC. Martindale: the Complete Drug Reference. 36th ed. London : Pharmaceutical Press; 2009. Available at: http://library2.mc.ntu.edu.tw/hcs/librarian/PFPUI/2HMake439I4NtT. (accessed 2009 March 31). 81. DRUGDEX system. Englewood, Colorado. Micromedex, Inc.2009. Available at: http://library2.mc.ntu.edu.tw/hcs/librarian/PFPUI/2HMake439I4NtT. (accessed 2009 March 31). 82. Brunton LL: Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York : McGraw-Hill; 2006. Available at: http://online.statref.com/TOC/TOC.aspx?FxId=75&SessionId=1001707VHJGOMNWG. (accessed at 2009 April 2). 83. Baxter K: Stockley's Drug Interactions. 7th ed. London: Pharmaceutical Press; 2006;827-44. 84. 行政院衛生署新聞:推動處方交付就醫者,提升藥事服務品質。Available at: http://www.doh.gov.tw/CHT2006/DM/SEARCH_RESULT.aspx. (accessed 2009 July 12). 85. 中央健康保險局:中央健康保險局業務執行報告-95年度。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=1&menu_id=4&webdata_id=1359&WD_ID=. (accessed 2009 July 6). 86. 陳正宗:慢性病患對慢性病連續處方箋認知與態度之探討–以台南縣為例[碩士論文];指導教授:陳麟慶(高雄醫學大學);2008. 87. 中央健康保險局:90年西醫門診感冒之就醫次數與平均每件醫療費用。臺北:中央健康保險局。Available at: http://www.nhi.gov.tw/. (accessed 2009 July 10). 88. 高淑真、李玉春、黃文鴻、李龍騰:全民健保糖尿病門診問題處方之分析-以北台灣為中心之研究。臺灣公共衛生雜誌 2006;25:58-64。 89. 藥師週刊:老人用藥守護神就是你!藥師週刊98年4月20日;1618期。 90. Rajska-Neumann A, Wieczorowska-Tobis K, Schulz M, Breborowicz A, Grzeskowiak E, Oreopoulos DG: Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland. Archives of Gerontology and Geriatrics 2007;44(Supplement 1):295-301. 91. Tozawa M, Iseki K, Iseki C, et al: Analysis of drug prescription in chronic haemodialysis patients. Nephrology Dialysis Transplantation 2002;17:1819-24. 92. Alkema GE, Wilber KH, Frey D, et al: Characteristics associated with four potential medication problems among older adults in Medicaid waiver services. Consultant Pharmacist 2008;23:396-403. 93. Chang CM, Liu PY, Yang YH, et al: Potentially inappropriate drug prescribing among first-visit elderly outpatients in Taiwan. Pharmacotherapy 2004;24:848-55. 94. 沈德依:社區老年人潛在性不適當用藥盛行率與相關因子之探討 [碩士論文];指導教授:季瑋珠(國立臺灣大學);2008。 95. 劉雅文:以2005年承保抽樣歸人檔分析高血壓病人之重複醫療資源利用情形 [碩士論文];指導教授:楊銘欽(國立臺灣大學);2008。 96. Malone DC, Abarca J, Skrepnek GH, Murphy JE, Armstrong EP, Grizzle AJ, Rehfeld RA, Woosley RL: Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Medical Care 2007;45:456-62. 97. Rupp MT, DeYoung M, Schondelmeyer SW: Prescribing problems and pharmacist interventions in community practice. Medical Care 1992;30:926-40. 98. 閻光濤:調查:大醫院藥師工作超量,1天服務450人。中央日報98年6月13日。 99. Buurma H, Schalekamp T, Egberts AC, De Smet PA: Compliance with national guidelines for the management of drug-drug interactions in Dutch community pharmacies. Annals of Pharmacotherpy 2007;41:2024-31. 100. Haugbolle LS, Sorensen EW, Haugbolle LS, Sorensen EW: Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma-interviewing patients at home. Pharmacy World & Science 2006;28:239-47. 101. 吳家雯:全民健康保險研究資料庫HMG-CoA Reductase Inhibitors處方型態及用藥安全性分析:自藥品交互作用觀點探討 [碩士論文];指導教授:何藴芳助理教授(國立臺灣大學);2005。 102. Perreault S, Blais L, Dragomir A, et al: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. European Journal of Clinical Pharmacology 2005;61:667-74. 103. Di Martino M, Degli Esposti L, Ruffo P, et al: Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. European Journal of Clinical Pharmacology 2005;61:225-30. 104. Lee YC, Huang KH, Huang YT: Adverse pharmaceutical payment incentives and providers' behavior: the emergence of GP-owned gateway pharmacies in Taiwan. Health Policy Plan 2007;22:427-35. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45456 | - |
dc.description.abstract | 研究背景:
國內於民國84年實施醫藥分業,藉由醫師與藥師的專業分工合作以增進病人健康,藥事專業服務品質是用藥安全中相當重要的一環。民眾就醫時,可選擇是否持交付處方箋至社區藥局調劑領藥,社區藥事人員可為民眾建立個人用藥紀錄並協助長期追蹤病人健康狀況。然而目前國內醫藥分業仍存在「雙軌制」,調劑服務場所除了社區藥局、醫院藥局之外,尚有診所附設調劑服務,藥事人員無論於何處執業,都應審慎評估處方,把關病人用藥安全。 研究目的: 本研究藉由全民健康保險申報資料探勘,期了解國內各調劑處所重複處方之調劑概況及處方適當性藥事評估情形,並探討藥事人員在調劑作業上可能遇到的問題,做為提升服務品質及用藥安全之參考。 研究方法: 利用全民健康保險研究資料庫2000至2007年百萬承保資料抽樣歸人檔,自新開立且有申報藥品調劑之全部處方中,以簡單隨機抽樣自各年抽取分別0.5%處方做為分析主體,研究指標為重複用藥(同藥理機轉、同學名及同品項);此外,另再從分析主體中篩選出含慢性疾病(糖尿病、高血壓及高脂血症)用藥之處方,以大於(含)4項口服降血糖藥(糖尿病處方)、同一類化學結構且降血糖藥理機轉重複(糖尿病處方)、降血壓藥理機轉重複(高血壓處方)及含有與statins間有潛在不良交互作用之藥品(高脂血症處方)等四項研究指標,分析處方適當性之藥事評估情形。本研究進一步比較健保特約藥局、醫院及診所間處方基本資料及各研究指標發生比例之差異,並以多元迴歸分析探求各研究指標之相關因素。 研究結果: 本研究納入分析的處方共計388,744張,於特約藥局調劑之處方有68,289張(17.6%)、醫院112,043張(28.8%)、診所208,410張(53.6%),八年間之處方釋出率平均為17.6%,以2005年之26.6%為最高。簡表申報處方佔總處方數55.5%,平均每張處方中品項數為3.7 ± 1.9項、給藥日份為7.1 ± 8.8天。在排除處方中的外用藥品後,有347,771張處方納入重複用藥分析,同藥理機轉、同學名、及同品項重複用藥之發生比例分別為17.4%、4.0%、1.7%,且在此八年間有逐年降低之趨勢,然而診所之此三類重複用藥皆顯著高於醫院及特約藥局(p=< 0.0001、< 0.0001、< 0.0001)。發生重複用藥之相關因子包括:處方中之品項數愈多、急診處方、診所調劑之簡表申報處方、開方醫師年齡愈大及開方到領藥日間距超過1天者,較易有重複用藥的情形;而病人年處方次數愈少、調劑藥事人員年齡愈小,較少發生重複用藥。 含降血糖用藥之處方共10,674張,超過4種口服降血糖藥之處方有101張(1.0%),在特約藥局、醫院、診所調劑者分別為7(佔社區藥局總處方數0.9%)、82(佔醫院總處方數1.0%)、12(佔診所總處方數0.5%)張;藥品屬同一類化學結構且降血糖藥理機轉重複者之發生比例為1.4%(152張),在特約藥局、醫院、診所調劑者分別為10(佔社區藥局總處方數1.3%)、91(佔醫院總處方數1.25%)、51(佔診所總處方數2.0%)張。含降血壓用藥處方共有32,109張,其中441張處方(1.4%)有降血壓藥理機轉重複情形,在特約藥局、醫院、診所調劑者分別為42(佔社區藥局總處方數1.6%)、314(佔醫院總處方數1.6%)、51(佔診所總處方數0.9%)。處方中含statins者計有3,423張,其中有210張(6.1%)處方含有與statins間有潛在不良交互作用之藥品,在特約藥局、醫院、診所調劑者分別為8(佔社區藥局總處方數3.7%)、184(佔醫院總處方數6.9%)、18(佔診所總處方數3.4%)張。此三類慢性疾病處方適當性評估相關因子包括:處方中之品項數愈多、急診處方,含此兩項因子者其處方不適當情形較為常見,而就醫醫療院所為醫學中心者則是較少發生。 結論: 在研究年度間,各類重複用藥發生比例有逐年降低之趨勢,然而各年均以診所調劑之處方發生比例最高;在慢性疾病用藥適當性評估中,醫院調劑之處方,除降血糖藥理機轉重複指標發生比例最低之外,其他三項指標皆高於特約藥局及診所。影響處方適當性評估之因素包括有處方藥品品項數愈多、急診處方、診所調劑之簡表申報處方、開方醫師年齡愈大、處方開立到領藥日期間距愈長,病人之年處方次數愈多,較容易發生處方不適當用藥的情形。為增進病人用藥安全,藥事人員於調劑時應確實依憑專業覆核處方。未來可針對多重慢性疾病及使用較多項藥品之病人適當處方覆核服務及評估研究,進一步了解國內慢性疾病之用藥概況及需求,對病人能有更完善的藥事照護,提升藥事專業服務品質。 | zh_TW |
dc.description.abstract | Background:
The separation of drug prescribing and dispensing has been implemented in Taiwan since 1995. The intimate collaboration between pharmacists and physicians is definitely beneficial to patients’health care. Quality pharmaceutical service is the key to safe medication use. The public should have the right to choose pharmacies of their own preference, either community or hospital pharmacies for prescription dispensing. Community pharmacists can help profiling patients’medication records and performing follow-ups for patients’ medication use and their health status. Currently, patients in Taiwan can have their prescription filled either at community pharmacies, hospital pharmacies, or quite contrast to advanced countries, even at primary-care clinics. Pharmacists, no matter practice settings are they at, are entitled to verifying medication orders to ensure medication safety. Objectives: The aims of the study was to investigate, by using the National Health Insurance Research Database (NHIRD), the incidence of therapeutic duplications and to evaluate medication appropriateness of prescriptions dispensed by various settings, namely community pharmacies, hospital pharmacies, and clinics. Factors associated with therapeutic duplications and medication appropriateness were also determined in the study. Methods: New prescriptions with dispensing records, from a cohort dataset of one-million enrollees of the NHIRD from year 2000 through 2007, were selected yearly by simple random sampling by a ratio of 0.5%. Study endpoints were therapeutic duplications in medication orders prescribed within one ambulatory visit. Three levels of therapeutic duplications were assessed, namely duplicated by therapeutic class, by generic name, or by identical medicine (same generic name, strength, and dosage form). In addition, if one prescription contained at least one oral hypoglycemia agent (OHA), antihypertensive agent, or statin, the prescription would then be selected for appropriateness evaluation and for comparison among practice settings. Respective endpoints were: (1) concomitant use of 4 or more OHAs and duplication of OHAs of the same chemical classes for prescriptions containing OHAs; (2) duplicated pharmacological mechanisms for prescriptions containing antihypertensives; and (3) with potentials for adverse drug-statin interactions for prescriptions containing statins. Multiple logistic regressions were performed to identify factors associated with these four endpoints. Results: In 388,744 sampled prescriptions, prescriptions dispensed by community pharmacies, hospital pharmacies, and clinics were 68,289 (17.6%), 112,043 (28.8%), and 208,410 (53.6%), respectively. The highest prescription release rate was seen in 2005 (26.6%). Prescriptions claimed by simplified processes accounted 55.5% of total prescriptions. The average items per prescription were 3.7 ± 1.9 medications with a supply of 7.1 ± 8.8 days. After excluding topical medications, a total of 347,771 prescriptions were enrolled for therapeutic duplication analyses. The rates for therapeutic class duplications, generic name duplications, and the duplication of identical medicines were 17.4%, 4.0%, and 1.7%, respectively. A trend of decreasing incidence in therapeutic duplications was observed among the eight years studies. However, clinics had higher rates of therapeutic duplications in each year for all three types of duplications (p<0.0001,<0.0001,<0.0001). Factors associated with therapeutic duplications included more medication items per prescription, ER prescriptions, prescriptions from clinics and claimed through simplified processes, elder prescriber, and the interval between prescription prescribing and dispensing>1 day. On the other hand, patients with fewer yearly prescriptions and younger pharmacists were negatively correlated with therapeutic duplications. There were 10,674 prescriptions containing at least one OHA. A hundred and one (1.0%) prescriptions contained 4 or more OHAs. Seven (accounted for 0.9% prescriptions) were dispensed at community pharmacies; 82 (accounted for 1.0% prescriptions) at hospital pharmacies and twelve (accounted for 0.5% prescriptions) at clinics. The incidence of duplicated OHAs of the same chemical classes was 1.4% (152 prescriptions), with the highest incidence occurring at clinics (2.0%; 51 prescriptions). There were 32,109 prescriptions containing at least one anti-hypertension agent. Pharmacological mechanism duplications were seen in 441 prescriptions (1.4%), including 42 (1.6%) at community pharmacies, 314 (1.6%) at hospital pharmacies, and 51 (0.9%) at clinics. Prescriptions containing statins amounted 3,423. There were 210 (6.1%) prescriptions detected for potential drug-statin interactions that were of clinical significance. Those dispensed at community pharmacies, hospital pharmacies, and clinics were 8 (3.7%), 184 (6.9%), and 18 (3.4%) prescriptions, respectively. We found that factors associated with medication inappropriateness included more medication items per prescription and ER prescriptions, whereas medical-center prescriptions was a protective factor. Conclusions: A trend of decreasing incidence in therapeutic duplications was observed among the eight years studies. Clinics had higher rates of therapeutic duplications in each year for all three types of duplications. Hospitals have the higher rates of medication inappropriateness than those of community pharmacies and clinics, except the endpoint that is duplication of OHAs of the same chemical classes for prescriptions containing OHAs. The factors associated with medication inappropriateness included more medication items per prescription, ER prescriptions, prescriptions from clinics and claimed through simplified processes, elder prescriber, the interval between prescription prescribing and dispensing>1 day, and the times of prescribing per patient per year. In order to enchance the medication use safety, pharmacists should be aimed at these characteristics when evaluating prescriptions. Studies of medication appropriateness in patients with multiple chronic diseases and long-term using medicines can be implemented in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:21:09Z (GMT). No. of bitstreams: 1 ntu-98-R94451005-1.pdf: 1589256 bytes, checksum: 93da294ca3f8718ecb24c0d4528f741f (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iii Abstract vi 圖目錄 x 表目錄 xi 第一章 緒論 1 第一節 研究背景 1 第二節 研究目的 2 第二章 文獻探討 3 第一節 處方適當性評估 3 第二節 國內調劑作業概況 19 第三節 國際間社區藥事服務 21 第三章 研究方法 27 第一節 研究材料 27 第二節 前置作業 30 第三節 研究架構 33 第四節 資料整理與統計分析 43 第四章 研究結果 45 第一節 藥品主檔分析 45 第二節 處方基本資料 48 第三節 處方適當性評估分析結果 61 第五章 討論 121 第一節 特約藥局調劑概況 121 第二節 重複用藥及慢性疾病處方適當性評估 123 第三節 研究特色與研究限制 138 第六章 結論 140 參考文獻 141 論文發表 150 附錄一 藥品之藥理機轉分類及研究使用編碼 151 | |
dc.language.iso | zh-TW | |
dc.title | 健保特約門診處方適當性(重複用藥)探討 | zh_TW |
dc.title | Medication Appropriateness (Therapeutic Duplications) of BNHI Outpatient Prescriptions | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳瓊雪 | |
dc.contributor.oralexamcommittee | 林慧玲,黃文鴻 | |
dc.subject.keyword | 特約藥局,調劑作業,處方適當性,重複用藥, | zh_TW |
dc.subject.keyword | community pharmaciy,medication appropriateness,therapeutic duplication,dispensing, | en |
dc.relation.page | 162 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-10-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.55 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。